InvestorsHub on MSN
Stoke Therapeutics shares slide after updated Phase 3 timeline
Shares of Stoke Therapeutics (NASDAQ:STOK) fell about 18% after the company outlined revised timelines for its Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback